These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26940138)

  • 1. GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo.
    Zhang Z; Ren X; Lu X; Wang D; Hu X; Zheng Y; Song L; Pang H; Yu R; Ding K
    Cancer Lett; 2016 May; 375(1):172-178. PubMed ID: 26940138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
    Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
    Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
    Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.
    Gerber DE; Gupta P; Dellinger MT; Toombs JE; Peyton M; Duignan I; Malaby J; Bailey T; Burns C; Brekken RA; Loizos N
    Mol Cancer Ther; 2012 Nov; 11(11):2473-82. PubMed ID: 22933705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
    Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
    Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer.
    Reinmuth N; Liersch R; Raedel M; Fehrmann F; Fehrmann N; Bayer M; Schwoeppe C; Kessler T; Berdel W; Thomas M; Mesters RM
    Int J Cancer; 2009 Apr; 124(7):1535-44. PubMed ID: 19115205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy.
    Wehler TC; Frerichs K; Graf C; Drescher D; Schimanski K; Biesterfeld S; Berger MR; Kanzler S; Junginger T; Galle PR; Moehler M; Gockel I; Schimanski CC
    Oncol Rep; 2008 Mar; 19(3):697-704. PubMed ID: 18288404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor-α.
    Nayeem MJ; Yamamura A; Hayashi H; Muramatsu H; Nakamura K; Sassa N; Sato M
    Life Sci; 2022 Jan; 288():120171. PubMed ID: 34822800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.
    Malavaki CJ; Roussidis AE; Gialeli C; Kletsas D; Tsegenidis T; Theocharis AD; Tzanakakis GN; Karamanos NK
    FEBS J; 2013 May; 280(10):2477-89. PubMed ID: 23374223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α.
    Feng H; Li Y; Yin Y; Zhang W; Hou Y; Zhang L; Li Z; Xie B; Gao WQ; Sarkaria JN; Raizer JJ; James CD; Parsa AT; Hu B; Cheng SY
    Neuro Oncol; 2015 Jun; 17(6):832-42. PubMed ID: 25468898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.
    Roh JW; Huang J; Hu W; Yang X; Jennings NB; Sehgal V; Sohn BH; Han HD; Lee SJ; Thanapprapasr D; Bottsford-Miller J; Zand B; Dalton HJ; Previs RA; Davis AN; Matsuo K; Lee JS; Ram P; Coleman RL; Sood AK
    Clin Cancer Res; 2014 May; 20(10):2740-50. PubMed ID: 24634380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70.
    Zhou Y; Ma J; Zhang J; He L; Gong J; Long C
    Oncol Rep; 2017 Jan; 37(1):313-322. PubMed ID: 28004121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
    Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angelicin inhibits human lung carcinoma A549 cell growth and migration through regulating JNK and ERK pathways.
    Li G; He Y; Yao J; Huang C; Song X; Deng Y; Xie S; Ren J; Jin M; Liu H
    Oncol Rep; 2016 Dec; 36(6):3504-3512. PubMed ID: 27748898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDGFRα and β play critical roles in mediating Foxq1-driven breast cancer stemness and chemoresistance.
    Meng F; Speyer CL; Zhang B; Zhao Y; Chen W; Gorski DH; Miller FR; Wu G
    Cancer Res; 2015 Feb; 75(3):584-93. PubMed ID: 25502837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
    Zhang P; Gao WY; Turner S; Ducatman BS
    Mol Cancer; 2003 Jan; 2():1. PubMed ID: 12537587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
    Decaudin D; de Cremoux P; Sastre X; Judde JG; Nemati F; Tran-Perennou C; Fréneaux P; Livartowski A; Pouillart P; Poupon MF
    Int J Cancer; 2005 Feb; 113(5):849-56. PubMed ID: 15499612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
    Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
    Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.